Asthma app study data on ResearchKit shows mixed results for patient … – MedCity News


MedCity News

Asthma app study data on ResearchKit shows mixed results for patient
MedCity News
The company, a spin-off of LifeMap Sciences, noted that preliminary data for Asthma Health showed that more than half of users “not only complete the e-consent process, they also come back the very next day to use the app. This is a very high rate of

and more »

View full post on asthma – Google News

Are only 7% of asthma sufferers using inhalers the right way? – MedCity News


International Business Times AU

Are only 7% of asthma sufferers using inhalers the right way?
MedCity News
The charity Asthma UK is making an effort to increase care for patients who aren't using their inhalers the correct way, which leads to use of stronger inhalers that aren't actually necessary. This insight comes after a separate U.S. study found that
Experts Evaluate Use of Allergy And Asthma DevicesInternational Business Times AU

all 2 news articles »

View full post on asthma – Google News

Medication monitoring company for asthma, COPD attracts $14.5M – MedCity News

Medication monitoring company for asthma, COPD attracts $14.5M
MedCity News
propeller health Android app Propeller Health, which developed an FDA-cleared sensor to track where and when patients with asthma, COPD and other respiratory diseases use their inhalers and take medication related to their condition, has closed a
Madison company Propeller Health raises $14.5 millionWisconsin State Journal
Propeller Health gets $14.5 million in funding, nabs Chris Hogg as COOSan Francisco Business Times (blog)
Propeller Health Raises $14.5M for its Respiratory Disease SensorsXconomy
CNNMoney –Milwaukee Journal Sentinel
all 9 news articles »

View full post on asthma – Google News

In late-stage study, Novartis finds asthma drug effective at reducing itch … – MedCity News

In late-stage study, Novartis finds asthma drug effective at reducing itch
MedCity News
ZURICH (Reuters) – Swiss drugmaker Novartis said on Saturday its drug omalizumab was almost doubly effective in improving quality of life for patients with a severe form of hives, compared with a placebo, according to a late-stage study. The third and

View full post on asthma – Google News